期刊文献+

两种方案治疗小儿癫痫的成本-效用比较 被引量:3

Cost-utility Analysis of Two Therapeutic Schemes for Epileptic Children
下载PDF
导出
摘要 目的评价两种治疗小儿癫痫的方案的疗效和经济性,探索成本-效用方法的应用。方法对63例小儿癫痫患者分为两组(A:门诊随访组,B:住院治疗组),使用自编小儿癫痫生命质量量变表对患者进行评价,提取评分法获得效用值,进行成本-效用分析。结果B组的成本-效用比(CUR)为32169.49元/QALY,A组的CUR值为38350.15元/QALY,敏感度分析得到一致结果,增量成本效用分析表明每增加1QALY,A组至少需追加花费23892.69元,故认为B方案在一定条件下更为经济、有效。结论对于慢性病患者采用CUA分析,能够全面评价患者生命质量,保证卫生资源的合理利用。 OBJECTIVE To evaluate the economic effectiveness in different therapeutic schemes for the treatment of children with epilepsy,and explore the methodological of cost-utility analysis(CUA). METHODS 63children with epilepsy were seleted prospectively,These patients were divided into two groups which received different therapeutic schemes (A :ambulatory follow-up treatment group,B:hospitalizcaion group). Quality of life (QOL)were measured with self-administered instrument of epilepsy. Utility scores were obtained so as to conduct CUA. RESULTS after 120 day's follow-up,average cost per quality-adjusted life year(QALY)for group B was 32169.49 yuan (RMB), and group A was 38350. 15 yuan (RMB) respectively. Sensitivity analysis also were similar results. Incremental cost analyisis show that extra cost per QALY gained by group A was 23892.69 yuan (RMB). CONCLUSION Base on this study,B scheme may be cost-saving for children with epilepsy. CUA is a valuable source of information which has resource implications for the health services.
出处 《海峡药学》 2006年第5期164-166,共3页 Strait Pharmaceutical Journal
关键词 成本-效用分析 药物经济学 小儿癫痫 Epilepsy Cost-utlity analysis Pharmacoeconomics
  • 相关文献

参考文献5

二级参考文献6

共引文献141

同被引文献34

  • 1陈华,洪黛玲,陈建军.癫痫患儿家长抑郁水平及相关因素的调查分析[J].现代护理,2004,10(10):890-891. 被引量:9
  • 2蒋庆琅 方积乾(译).寿命表及其应用[M].上海:上海翻译出版公司,1984.185-190.
  • 3蒋庆琅,著,方积乾译.寿命表及其应用[M].上海:上海翻译出版公司,1984:72-96.
  • 4国家癫痫项目办公室.农村癫痫防治管理项目培训教材.2010.
  • 5卫生部疾控局,农村地区癫痫防治管理项目指导组.中国农村地区癫痫防治管理项目实施方案.2010.
  • 6Murray CJ,Lopez AD. The global burde of disease: a comprehensive assessmem of mortality and disability from diseases, injuries and risk factors in 1990, and projected to 2020. Cambridge : Harvard University Press, 1996 : 91-98.
  • 7Forbes R. Cost-utility of vagus nerve stimulation (VNS) therapy for medically refractory epilepsy--an update. Seizure, 2008, 17 (4):387-388.
  • 8Vera-Llonch M, Brandenburg NA, Oster G. Cost-effectiveness of add-on therapy with pregabalin in patients with refractory partial epilepsy. Epilepsia, 2008,49 ( 3 ) : 431-437.
  • 9Diaz S, Argumosa A, de La Horga Parte JF, et al. Analysis of the cost-effectiveness of treatment for refractory partial epilepsy: a simulation model for pregabalin and levetiracetam. Rev Neurol, 2007,45 (8) : 460-467.
  • 10Wiebe S. Burden of intractable epilepsy. Adv Neurol, 2006,97 : 1-4.

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部